<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="180683">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742560</url>
  </required_header>
  <id_info>
    <org_study_id>HuLuc63-1703</org_study_id>
    <secondary_id>2007-006677-83</secondary_id>
    <nct_id>NCT00742560</nct_id>
  </id_info>
  <brief_title>A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma</brief_title>
  <official_title>A Phase 1b/2, Multicenter, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b/2, Multicenter, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti
      CS1 Monoclonal IgG1 Antibody) in Combination with Lenalidomide and Dexamethasone in Subjects
      with Relapsed Multiple Myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 Portion: Maximum tolerated dose</measure>
    <time_frame>During first 4 weeks of elotuzumab dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 portion: Objective response according to the International Myeloma Working group Uniform Response Criteria</measure>
    <time_frame>From screening through 60-day follow up period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile of elotuzumab</measure>
    <time_frame>From screening through 60-day follow up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of elotuzumab</measure>
    <time_frame>From screening through 60-day follow up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of elotuzumab</measure>
    <time_frame>From screening through 60-day follow up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti tumor activity of elotuzumab</measure>
    <time_frame>From screening through 60-day follow up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 portion: Objective response according to the International Myeloma Working group Uniform Response Criteria</measure>
    <time_frame>From screening through 60-day follow up period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Hematologic Cancer</condition>
  <arm_group>
    <arm_group_label>elotuzumab, lenalidomide and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>elotuzumab (lower dosage), lenalidomide and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the phase 2 portion, patients are randomized to arm 1 or arm 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>elotuzumab (higher dosage), lenalidomide and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the phase 2 portion, patients are randomized to arm 1 or arm 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>elotuzumab (HuLuc63)</intervention_name>
    <description>Humanized Anti-CS1 Monoclonal IgG1 Antibody</description>
    <arm_group_label>elotuzumab, lenalidomide and dexamethasone</arm_group_label>
    <arm_group_label>elotuzumab (lower dosage), lenalidomide and dexamethasone</arm_group_label>
    <arm_group_label>elotuzumab (higher dosage), lenalidomide and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>25 mg PO days 1 though 21 of each 28 day cycle</description>
    <arm_group_label>elotuzumab, lenalidomide and dexamethasone</arm_group_label>
    <arm_group_label>elotuzumab (lower dosage), lenalidomide and dexamethasone</arm_group_label>
    <arm_group_label>elotuzumab (higher dosage), lenalidomide and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>40 mg PO days 8 and 22; 28 mg PO and 8 mg IV days 1 and 15 of each 28 day cycle.</description>
    <arm_group_label>elotuzumab, lenalidomide and dexamethasone</arm_group_label>
    <arm_group_label>elotuzumab (lower dosage), lenalidomide and dexamethasone</arm_group_label>
    <arm_group_label>elotuzumab (higher dosage), lenalidomide and dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older with a confirmed diagnosis of MM and documentation of one to
             three prior therapies.

          2. Confirmed evidence of disease progression from immediately prior MM therapy or
             refractory to the immediately prior treatment.

          3. Measurable disease M protein component in serum (at least 0.5 g/dL) and/or urine (if
             present), (&gt;=0.2 g excreted in a 24 hour collection sample). Subjects with free light
             chain only disease are excluded.

          4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.

          5. Creatinine clearance &gt;=50 mL/min measured by Cockcroft-Gault method.

          6. Hematologic parameters defined by:

               -  Absolute neutrophil count &gt;1000 cells/mm^3 without growth factors for 7 days.

               -  Platelets &gt;=75,000 cells/mm^3 (75 × 10^9/L), without platelet transfusion,
                  within 72 hours of screening evaluation.

               -  Hemoglobin &gt;=8 g/dL without red blood cell transfusion within 72 hours of
                  screening.

          7. Alanine aminotransferase (ALT) AND aspartate aminotransferase (AST) &lt;3 × upper limit
             of normal.

          8. Total bilirubin &lt;2 × upper limit of normal, direct bilirubin &lt;2.0 mg/dL.

          9. Negative urine pregnancy test in women of childbearing potential at screening and
             prior to prescribing lenalidomide. Females of childbearing potential (FCBP) must
             either commit to continued abstinence from heterosexual intercourse or begin
             acceptable methods of birth control for 28 days prior to prescribing lenalidomide.
             Men must agree to use a latex condom during sexual contact with FCBP even if they
             have had a successful vasectomy, and must agree not to donate semen during study drug
             therapy and for a period of time after therapy.

         10. Able to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use protected health information (in accordance
             with national and local subject's privacy regulations).

         11. Able to take aspirin daily as prophylactic anticoagulation therapy (subjects
             intolerant to aspirin may use warfarin or low-molecular-weight heparin).

        Exclusion Criteria:

          1. Prior malignancy, except for adequately treated basal cell or squamous cell skin
             cancer, in-situ cervical cancer, or other cancer from which the subject has been
             disease-free for at least 2 years.

          2. Active or prior plasma cell leukemia (defined as either 20% of peripheral WBC
             comprised of plasma/CD138+ cells or an absolute count of 2 x 10^9/L).

          3. Uncontrolled medical problems such as diabetes mellitus, coronary artery disease,
             hypertension, unstable angina, arrhythmias, pulmonary disease, and symptomatic heart
             failure.

          4. Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma
             cell dyscrasia.

          5. Treatment with any investigational drug within 2 weeks or 3 half lives (whichever is
             longer) of the first dose of elotuzumab.

          6. Use of corticosteroids, thalidomide, bortezomib, or cytotoxic chemotherapy within 2
             weeks of the first dose of elotuzumab except for steroids with little or no systemic
             absorption (ie, topical or inhaled steroids).

          7. Prior lenalidomide therapy.

          8. Prior peripheral stem-cell transplant within 12 weeks of the first dose of
             elotuzumab.

          9. Treatment with nitrosoureas, such as carmustine (BiCNU), nitrogen mustard agents, or
             melphalan, within 6 weeks of first dose of elotuzumab.

         10. Neuropathy &gt;=Grade 3 or painful neuropathy &gt;=Grade 2 (National Cancer Institute
             Common Terminology Criteria for Adverse Events [NCI CTCAE] v3.0).

         11. Known active infections requiring IV antibiotic, antiviral, or antifungal therapy.

         12. Hypersensitivity to recombinant proteins or excipients in elotuzumab, lenalidomide,
             or dexamethasone.

         13. Female subjects who are pregnant or breastfeeding.

         14. Subjects with serum calcium (corrected for albumin) &gt;= 12 mg/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louie Naumovski, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63587</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63591</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63588</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63586</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63592</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63589</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63585</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63582</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63584</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63583</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63562</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63564</name>
      <address>
        <city>Lyon, Cedex 8</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63567</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63565</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63502</name>
      <address>
        <city>Tours Cedex</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63570</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63569</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 24, 2016</lastchanged_date>
  <firstreceived_date>August 25, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
